GlassScriptPhysician profile
Robert Guy Ferland
NPI 1447256490
$4,876.88
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $1,426 · 2021: $1,280 · 2022: $758 · 2023: $13.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,027.80 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $565.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $372.63 | 2019-2022 | |
| Allergan, INC. | $372.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $256.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $251.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $211.35 | 2019-2022 | |
| Pfizer INC. | $163.78 | 2019-2021 | |
| Abbvie INC. | $153.93 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $113.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $98.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.79 | 2021 | |
| Supernus Pharmaceuticals, INC. | $92.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $90.89 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $69.20 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.12 | 2022 | |
| Amgen INC. | $63.26 | 2019-2022 | |
| Astellas Pharma US INC | $62.38 | 2020-2021 | |
| Eisai INC. | $55.93 | 2020 | |
| Biodelivery Sciences International, INC. | $45.80 | 2019-2021 | |
| Abbott Laboratories | $40.19 | 2021 | |
| Amarin Pharma, INC. | $36.33 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $35.19 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $25.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.23 | 2022 | |
| Daiichi Sankyo INC. | $18.48 | 2021 | |
| Assertio Therapeutics, INC. | $17.90 | 2019 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Phadia US INC. | $13.36 | 2022 | |
| Vistapharm, INC. | $13.14 | 2021 | |
| Antares Pharma, INC. | $12.27 | 2019 | |
| Horizon Therapeutics Plc | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ferland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.